Skærmbillede 2016-03-02 07.56.25

Den næste Genmab?

Vi har fundet et selskab som på mange områder minder om Genmab, dengang kursen var i 80 og markedsværdien var 4,5 milliarder DKK. Faktisk minder de selskaber opsigtsvækkende meget om hinanden. De har begge en solid cash position, har begge fået BreakThrough Designation af FDA og accelerated approval, de har begge kræftstoffer på markedet og de er begge i gang …

Read more.

---

Nye køb til porteføljen og status på 2016

Efter en tumultarisk indledning på 2016 er der nu så småt kommet ro på de finansielle markeder. Januar måned var en hård måned for alle aktionærer, men vi foretog en del dispositioner som er faldet heldigt ud i løbet af både januar og februar, ligesom vi har lagt grunden til fremtidige værdistigninger. Vi har blandt andet aggressivt øget vores position …

Read more.

---

Øger nok engang i Tank

Har suppleret op i positionen efter yderligere kursfald i EuroNav. 208 stk @ Kurs 8,9. Da eksponeringen mod Tank i porteføljen nu udgør 33% har jeg valgt at trimme beholdningen af Nordic American Tankers ned til 500. Solgt 200 stk @ 13,81.

Read more.

The gateway to small- and midcap stocks in Scandinavia. Steen has more than 15 years hands-on expericence in analysing and investing in stocks. He is a weekly contributor and analyst in “Aktieugebrevet”, one of the leading sources of independent analysis in Denmark.

Peter Hildebrandt, also known as “Akademikeren”, has been investing for more than 17 years. Mainly invests in Undervalued technology and biotech stocks and is currently rotating towards dividend stocks in energy and shipping.

I’m a ten year veteran of biotechnology, and currently pursuing my MBA from UCLA.  I use my knowledge of the industry and business to make my investing decisions.  I look for small to mid-cap biotech companies with innovative research and buy into their company during clinical trials.

Andreas is providing stock tips with deep fundamental research behind each stock he recommends. He is privately a portfolio manager at his own Investment company where he Invest in stocks, options, CFD’s etc. with a balanced long/short approach.

Jacob’s approach is to search for that which is undervalued and where the discount to the intrinsic value provides a large margin of safety. He believes sectors that are either out of favor or in distress typically offer the best opportunities.